STEPHANIE AKUNNE: Open Payments
NPI 1962809392 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,636 in 89 payments from 16 companies in 2025. Trend: 2023 $1,594 · 2024 $1,541 · 2025 $1,636
Food & beverage: $1,636
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 16 | $301 |
| ABBVIE INC. | 18 | $261 |
| Novo Nordisk Inc | 16 | $233 |
| AstraZeneca Pharmaceuticals LP | 7 | $185 |
| Axsome Therapeutics, Inc. | 5 | $125 |
| Lilly USA, LLC | 8 | $114 |
| Neurocrine BioSciences, Inc. | 1 | $104 |
| PFIZER INC. | 5 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Currax Pharmaceuticals LLC | 2 | $33 |
Products named: TRELEGY ELLIPTA, AIRSUPRA, Auvelity, VRAYLAR, MOUNJARO, QULIPTA, Wegovy, Ozempic.
Industry payments across LA — which companies pay providers there.
